Oxidative stress markers in patients with Behcet’s disease
DOI:
https://doi.org/10.15305/ijrci/v5i1/239Keywords:
Malondialdehyde, Nitric Oxide, Oxidative stress, Behcet’s Disease.Abstract
Aim: To evaluate the role of serum malondialdehyde (MDA) and nitric oxide (NO) as oxidative biomarkers in patients with Behcet’s disease (BD)
Methods: The case-control study included 44 cases and 44 controls from different areas of Duhok governorate, Iraq. All the subjects had undergone serological and hematological examinations.
Results: The male to female ratio noted was 1.1:1, and the age of patients ranged between 10-63 years. The mean age of the subjects was 37 years at presentation. Serum MDA level, ESR, and total number of granulocytes were significantly higher in patients with BD in comparison to healthy controls. Furthermore, mean serum NO and the number of lymphocytes were significantly lower in BD patients compared to controls. However, total white blood cell count and average number of monocytes were comparable in both the groups.
Conclusion: The study indicated the role of MDA and NO in the pathogenesis and progression of Behcet’s disease. Further research is warranted to explore its implication in diagnosis and treatment of BD.
References
Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behcet’s disease. Yonsei Med J 2012;53(1):35-42.
Birengel S, Yalçındağ FN, Yalçındağ A, Sahli E, Batıoğlu F. Urokinase plasminogen activator receptor levels in Behcet’s disease. Thromb Res 2011;128(3):274-6.
Kaya T. Genetics of Behçet’s Disease. Patholog Res Int 2012.
Hosaka A, Miyata T, Shigematsu H, Shigematsu K, Okamoto H, Ishii S, et al. Long-term outcome after surgical treatment of arterial lesions in Behcet disease. J VascSurg 2005;42(1):116-21.
Harzallah O, Kerkeni A, Baati T, Mahjoub S. Oxidative stress: correlation with Behcet’s disease duration, activity and severity. Eur J Intern Med 2008;19(7):541-7.
Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. ClinChim Acta 2007;380(1-2):50-8.
Taysi S, Kocer I, Memisogullari R, Kiziltunc A. Serum oxidant/antioxidant status in patients with Behcet’s disease. Ann Clin Lab Sci 2002;32(4):377-82.
Buldanlioglu S, Turkmen S, Ayabakan HB, Yenice N, Vardar M, Dogan S, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behcet’s disease. Br J Dermatol 2005;153(3):526-30.
Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet’s disease. Br J Ophthalmol 2004;88(10):1256-8.
Köse K, Yazici C, Aşçioğlu Ö. The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet’s disease. Clinical Biochemistry 2001;34(2):125-9.
Sahin M, Arslan C, Naziroglu M, Tunc SE, Demirci M, Sutcu R, et al. Asymmetric Dimethylarginine and Nitric Oxide Levels as Signs of Endothelial Dysfunction in Behcet’s Disease. Annals of Clinical & Laboratory Science 2006;36(4):449-54.
Zubakova R. Analysis of the mechanisms influencing the expression of blood pressure regulating systems: Heidelberg University 2007.
Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995;38(2):87-104.
Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A. Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behcet’s disease. Rheumatology 2005;44(5):614-7.
Orem A, Erturk M, Cimsit G, Kural BV. Effect of plasma from patients with Behcet’s disease on the production of nitric oxide in cultured human umbilical vein endothelial cells. Med PrincPract 2004;13(1):35-8.
Arayssi T, Hamdan A. New insights into the pathogenesis and therapy of Behcet’s disease. CurrOpinPharmacol 2004;4(2):183-8.
Sun J, Zhang X, Broderick M, Fein H. Measurement of Nitric Oxide Production in Biological Systems by Using Griess Reaction Assay. Sensors 2003;3:276-84.
Davatchi F. Behcet’s disease: global perspective. Indian Journal of Rheumatology 2007;2(2):65-71.
Hussien C. Validity of Pathergy Test in Patients With Behçet`s Disease [High Diploma]. College of Medicine: University of Dohuk; 2008.
Gaznai H. The frequency of Pathergy test in Behçet disease in Erbil City: Hawler Medical University; 2012.
Abu-Ameerh MA, Mohammed SF, Mohammad MT, Ababneh OH, Al-Bdour MD. Ocular manifestations of Behçet’s disease in Jordanian patients. Saudi Journal of Ophthalmology 2013;27(4):247-51.
Davatchi F, Shahram F, Chams C, Chams H, Nadji A. Behçet’s disease. Acta Med Iran 2005;43(4):233-42.
Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s Disease. The New England Journal of Medicine 1999;341(17):1284-91.
Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA. Behçet’s disease: comparing 3 decades of treatment response at the National Eye Institute. Canadian Journal of Ophthalmology / Journal Canadiend’Ophtalmologie 2008;43(4):468-72.
Kontogiannis V, Poweli R. Behçet’s disease. Postgrad Med J 2000;76:629–37.
Boura P, Tselios K, Skendros P, Kamali S, Sarantopoulos A, Raptopoulou-Gigi M. Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia 2007;11(4):210-5.
Mandelcorn J, Bray P, Kong H. The Management of Behcet’s Disease – A Multi-disciplinary Approach. University of Toronto Medical Journal 2003;80 (2):94-7.
Tunes R, Santiago M. Behcet’s Syndrome: Literature Review. Current Rheumatology Reviews 2009;5(1):64-82.
Seyahi E, Yurdakul S. Behcet’s Syndrome and Thrombosis. Mediterr J Hematol Infect Dis 2011;3(1):e2011026.
Al-Araji A, Sharquie K, Al-Rawi Z. Prevalence and patterns of neurological involvement in Behcet’s disease: a prospective study from Iraq. J NeurolNeurosurg Psychiatry 2003;74(5):608-13.
Akman-Demir G, Serdaroglu P. Neuro-Behçet’s disease: a practical approach to diagnosis and treatment. Practical Neurology 2002;2:340-7.
Shahram F, Nadji A, Jamshidi A, Chams H, Chams C, Shafaie N, et al.Behcet’s disease in Iran, analysis of 5,059 cases. Arch Iranian Med 2004;7(1):9–14.
Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al.Behcet’s disease: from East to West. ClinRheumatol 2010;29(8):823-33.
Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet’s disease: an update. CurrOpinRheumatol 2011;23(1):24-31.
Ceylan N, Bayraktaroglu S, Erturk SM, Savas R, Alper H. Pulmonary and Vascular Manifestations of Behçet Disease: Imaging Findings. American Journal of Roentgenology 2010;194(2):W158-W64.
Mahgoub M, Raslan H, Assal H, Gheita T, Fikry I, Abd El-Moniem M, et al. Oxidant/Antioxidant Status in Patients with Behçet Disease. Macedonian Journal of Medical Sciences 2010;3(1):37-42.
Kim J, Chang H, Lee S, Kim J, Kim K, Lee S, et al. Endothelial nitric oxide synthase gene polymorphisms in Behcet’s disease and rheumatic diseases with vasculitis. Ann Rheum Dis 2003;62:1083–7.
Yapışlar H, Aydogan S, Borlu M, Ascioglu Ö. Decreased nitric oxide and increased platelet aggregation levels in patients with Behçet’s disease. Thromb Res 2007;119(4):461-5.
Nakao K, Isashiki Y, Sonoda S, Uchino E, Shimonagano Y, Sakamoto T. Nitric oxide synthase and superoxide dismutase gene polymorphisms in Behcet disease. Arch Ophthalmol 2007;125(2):246-51.
Orem A, Vanizor B, G Ç, Kıran E, Deger O, Malkoç M. Decreased Nitric Oxide Production in Patients with Behçet’s Disease. Dermatology 1999;198:33–6.
Neves FS, Spiller F. Possible mechanisms of neutrophil activation in Behçet’s disease. International Immunopharmacology 2013;17(4):1206-10.
Onder M, Gurer M. The multiple faces of Behçet’s disease and its aetiological factors. Journal of European Academy of Dermatology and Venereology 2001;15:126–36.
Kiraz S, Ertenli I, Çalgüneri M, Öztürk M, Haznedaroglu I, Altun B, et al.Interactions of nitric oxide and superoxide dismutase in Behcet’s disease. ClinExpRheumatol 2001;19(14):S25-S9.
Chambrun M, Bertrand Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmunity Reviews 2012;11:687–98.
Additional Files
Published
Issue
Section
License
Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
